Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for AMX0035, its proprietary combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO) for treating Wolfram syndrome. This designation follows a positive opinion from the Committee for Orphan Medicinal Products…
Puma Biotechnology, a biopharmaceutical company, has released its financial results for the second quarter ending June 30, 2024. Comparisons are made between Q2 2024 and Q2 2023, unless specified otherwise. Product revenue, which comes entirely from sales of NERLYNX®, Puma’s…
Vertex Announces Q2 2024 Financial Results, Raises Full-Year Product Revenue Guidance Vertex today reported consolidated financial results for the second quarter ending June 30, 2024, and increased its full-year product revenue guidance to $10.65 to $10.85 billion. “Vertex achieved another…
Lilly announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.…
Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to identify and develop blood-based biomarkers for tau pathology in Alzheimer’s disease (AD). The goal is to create new tests that measure tau burden in the brain, offering crucial insights into…
Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain Vertex Pharmaceuticals today revealed that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for suzetrigine, an investigational oral NaV1.8 pain signal inhibitor designed to…
Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along with its R&D, operational, and commercial sites, into Roche’s global…
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on updating the Wegovy® (semaglutide 2.4 mg) label. This update reflects data from the SELECT cardiovascular outcomes…
PROTEINA Co., Ltd., in partnership with Seoul National University (SNU) and Seoul National University Hospital (SNUH), has announced groundbreaking research published in Nature Biomedical Engineering. The study introduces a novel method for personalizing treatment for acute myeloid leukemia (AML) patients…
Verastem Oncology, a biopharmaceutical company focused on developing new cancer treatments, announced its intention to offer and sell shares of common stock and accompanying warrants to purchase common stock. The offering will also include pre-funded warrants, which can be purchased…
Verastem Oncology, a biopharmaceutical company focused on cancer treatments, announced the pricing of an underwritten public offering. The offering includes 13,333,334 shares of common stock and accompanying warrants to purchase up to 13,333,334 shares at $3.00 per share and warrant.…
Bristol Myers Squibb today announced the validation of its near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi) as part of a mid-year update on its environmental initiatives. This milestone underscores the company’s progress in reducing emissions…
